{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:53:13Z","timestamp":1792183993973,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.pharma.2012.02.003","type":"journal-article","created":{"date-parts":[[2012,4,26]],"date-time":"2012-04-26T22:33:14Z","timestamp":1335479594000},"page":"133-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Les traitements hypo-uric\u00e9miants disponibles dans la goutte"],"prefix":"10.1016","volume":"70","author":[{"given":"P.","family":"Richette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.pharma.2012.02.003_bib0005","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.pharma.2012.02.003_bib0010","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in rheumatology guideline for the management of gout","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.pharma.2012.02.003_bib0015","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.pharma.2012.02.003_bib0020","first-page":"908","article-title":"A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis","volume":"22","author":"Ferraz","year":"1995","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.pharma.2012.02.003_bib0025","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0002-9343(87)90441-4","article-title":"Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study","volume":"82","author":"Campion","year":"1987","journal-title":"Am J Med"},{"issue":"8","key":"10.1016\/j.pharma.2012.02.003_bib0030","first-page":"1383","article-title":"Withdrawal of longterm antihyperuricemic therapy in tophaceous gout","volume":"20","author":"van Lieshout-Zuidema","year":"1993","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.pharma.2012.02.003_bib0035","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad","year":"2004","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.pharma.2012.02.003_bib0040","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4065\/81.7.925","article-title":"Gout medication treatment patterns and adherence to standards of care from a managed care perspective","volume":"81","author":"Sarawate","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.1016\/j.pharma.2012.02.003_bib0045","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/ard.2008.091462","article-title":"A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300\u2013600mg\/day versus benzbromarone 100\u2013200mg\/day in patients with gout","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.pharma.2012.02.003_bib0050","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11926-009-0019-z","article-title":"A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout","volume":"11","author":"Chao","year":"2009","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"10.1016\/j.pharma.2012.02.003_bib0055","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrrheum.2009.236","article-title":"Update on gout: new therapeutic strategies and options","volume":"6","author":"Terkeltaub","year":"2010","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.pharma.2012.02.003_bib0060","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.pharma.2012.02.003_bib0065","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.30119","article-title":"Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment","volume":"63","author":"Stamp","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"46","key":"10.1016\/j.pharma.2012.02.003_bib0070","first-page":"ra62","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response","volume":"2","author":"Picard","year":"2011","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.pharma.2012.02.003_bib0075","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"23","key":"10.1016\/j.pharma.2012.02.003_bib0080","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.pharma.2012.02.003_bib0085","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s10067-010-1457-8","article-title":"International position paper on febuxostat","volume":"29","author":"Jansen","year":"2010","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.pharma.2012.02.003_bib0090","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.pharma.2012.02.003_bib0095","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jbspin.2004.07.006","article-title":"Current management of gout in patients unresponsive or allergic to allopurinol","volume":"71","author":"Bardin","year":"2004","journal-title":"Joint Bone Spine"},{"issue":"10","key":"10.1016\/j.pharma.2012.02.003_bib0100","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/ajh.2008.245","article-title":"Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients","volume":"21","author":"Hamada","year":"2008","journal-title":"Am J Hypertens"},{"issue":"2","key":"10.1016\/j.pharma.2012.02.003_bib0105","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2169\/internalmedicine.49.2597","article-title":"Effect of fenofibrate on uric acid metabolism and urate transporter 1","volume":"49","author":"Uetake","year":"2010","journal-title":"Intern Med"},{"issue":"1","key":"10.1016\/j.pharma.2012.02.003_bib0110","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/BF00163854","article-title":"Two independent mutational events in the loss of urate oxidase during hominoid evolution","volume":"34","author":"Wu","year":"1992","journal-title":"J Mol Evol"},{"issue":"9711","key":"10.1016\/j.pharma.2012.02.003_bib0115","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0140-6736(09)60883-7","volume":"375","author":"Richette","year":"2010","journal-title":"Gout. Lancet"},{"issue":"10","key":"10.1016\/j.pharma.2012.02.003_bib0120","first-page":"2093","article-title":"Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study","volume":"34","author":"Richette","year":"2007","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.pharma.2012.02.003_bib0125","first-page":"1955","article-title":"Learning how and when to employ uricase as bridge therapy in refractory gout","volume":"34","author":"Terkeltaub","year":"2007","journal-title":"J Rheumatol"},{"issue":"9760","key":"10.1016\/j.pharma.2012.02.003_bib0130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(10)60665-4","article-title":"Gout therapeutics: new drugs for an old disease","volume":"377","author":"Burns","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pharma.2012.02.003_bib0135","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.addr.2007.06.011","article-title":"PEG-uricase in the management of treatment-resistant gout and hyperuricemia","volume":"60","author":"Sherman","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"10.1016\/j.pharma.2012.02.003_bib0140","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/art.22403","article-title":"Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout","volume":"56","author":"Sundy","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.pharma.2012.02.003_bib0145","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1002\/art.24201","article-title":"Gout management: let's get it right this time","volume":"59","author":"Sundy","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.pharma.2012.02.003_bib0150","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1002\/art.23810","article-title":"Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study","volume":"58","author":"Sundy","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharma.2012.02.003_bib0155","first-page":"CD008335","article-title":"Pegloticase for chronic gout","volume":"3","author":"Anderson","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.pharma.2012.02.003_bib0160","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1002\/art.23993","article-title":"Resolution of gouty tophi after twelve weeks of pegloticase treatment","volume":"58","author":"Baraf","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.pharma.2012.02.003_bib0165","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450912000296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450912000296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:29:47Z","timestamp":1757719787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450912000296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0003450912000296"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2012.02.003","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les traitements hypo-uric\u00e9miants disponibles dans la goutte","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2012.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}